Bayer Cost of Goods Sold 2010-2024 | BAYRY

Bayer cost of goods sold from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Bayer Annual Cost of Goods Sold
(Millions of US $)
2023 $21,374
2022 $20,936
2021 $19,895
2020 $21,861
2019 $19,563
2018 $20,089
2017 $12,865
2016 $22,458
2015 $23,494
2014 $26,940
2013 $25,699
2012 $24,512
2011 $25,036
2010 $22,711
2009 $21,107
Bayer Quarterly Cost of Goods Sold
(Millions of US $)
2024-06-30 $5,081
2024-03-31 $5,931
2023-12-31 $4,839
2023-09-30 $5,237
2023-06-30 $5,145
2023-03-31 $6,154
2022-12-31 $4,805
2022-09-30 $4,278
2022-06-30 $6,045
2022-03-31 $5,809
2021-12-31 $4,170
2021-09-30 $4,584
2021-06-30 $5,477
2021-03-31 $5,664
2020-12-31 $4,357
2020-09-30 $7,943
2020-06-30 $4,424
2020-03-31 $5,136
2019-12-31 $4,487
2019-09-30 $4,162
2019-06-30 $4,944
2019-03-31 $5,970
2018-12-31 $7,084
2018-09-30 $5,240
2018-06-30 $4,188
2018-03-31 $3,576
2017-12-31 $-1,155
2017-09-30 $3,015
2017-06-30 $5,630
2017-03-31 $5,375
2016-12-31 $5,780
2016-09-30 $5,388
2016-06-30 $5,680
2016-03-31 $5,611
2015-12-31 $5,821
2015-09-30 $5,514
2015-06-30 $5,876
2015-03-31 $6,282
2014-12-31 $6,813
2014-09-30 $6,559
2014-06-30 $6,969
2014-03-31 $6,599
2013-12-31 $6,791
2013-09-30 $6,115
2013-06-30 $6,449
2013-03-31 $6,344
2012-12-31 $6,197
2012-09-30 $5,864
2012-06-30 $6,224
2012-03-31 $6,227
2011-12-31 $6,412
2011-09-30 $6,057
2011-06-30 $6,501
2011-03-31 $6,066
2010-12-31 $6,212
2010-09-30 $5,385
2010-06-30 $5,697
2010-03-31 $5,418
2009-12-31 $5,872
2009-09-30 $5,115
2009-06-30 $5,168
2009-03-31 $4,952
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94